NTRK3 and adenoid cystic carcinoma: Recognition of these neoplasms is of paramount importance because they differ prognostically and therapeutically from conventional high-grade TNBC: many show low rates of recurrence or metastasis and harbor molecular drivers that may be targetable (e.g., ETV6–NTRK3 fusion in secretory carcinoma [33,34,35], MYB translocations in adenoid cystic carcinoma) [36,37,38].